Clinical trials: Persistent Corneal Epithelial Defect
- Condition Persistent Corneal Epithelial Defect
- Funder type Industry (pharma, biotech, devices)
- Age group Children (under 18)
Persistent Corneal Epithelial Defect
A Study to Evaluate the Safety and Efficacy of NEXAGON® (Lufepirsen Ophthalmic Gel) in Subjects With PCED
This study is to evaluate the safety and efficacy of NEXAGON® (lufepirsen ophthalmic gel) (NEXAGON) in subjects with persistent corneal epithelial defects (PCED).
- Trial name
- NEXPEDE-1 (NCT05966493)
- Testing
- lufepirsen high dose, Vehicle, lufepirsen low dose
- Where
- 28 sites in United States, Germany and 2 more
- Volunteers
- 84 people
- Sponsor
- Glaukos Corporation
Corneal Persistent Epithelial Defect
NEXAGON for the Treatment of Corneal Persistent Epithelial Defects Following Severe Ocular Injuries
This study will enroll participants with a non-infected, corneal persistent epithelial defect (PED) resulting from an ocular chemical and/or thermal ocular injury which is non-responsive or refractory to current standard of care…
- Trial name
- EXPEDE (NCT04081103)
- Testing
- Nexagon® (lufepirsen) High Dose Concentration, Nexagon® (lufepirsen) Low Dose Concentration, Vehicle
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- Glaukos Corporation
Persistent Corneal Epithelial Defect
Study of DE-105 Ophthalmic Solution in Patients With Persistent Corneal Epithelial Defect
Safety and efficacy of DE-105 ophthalmic solution in patients with persistent corneal epithelial defect will be evaluated. Dose-dependent efficacy will be evaluated as well.
- Trial name
- NCT00988494
- Testing
- DE-105 ophthalmic solution
- Where
- Japan
- Volunteers
- 45 people
- Sponsor
- Santen Pharmaceutical Co., Ltd.